# GetRetatrutide.ca

Evidence-based information about retatrutide (LY3437943) for Canadians — an investigational triple-agonist (GIP/GLP-1/glucagon) weight loss treatment in Phase 3 clinical trials. Not yet approved by Health Canada or the FDA.

## Key pages

- [Home](https://getretatrutide.ca/): Overview, key stats, comparison table, FAQ
- [What is Retatrutide?](https://getretatrutide.ca/what-is-retatrutide/): Mechanism of action, triple-agonist explanation, clinical development timeline
- [Clinical Trials](https://getretatrutide.ca/clinical-trials/): TRIUMPH-1 through TRIUMPH-5 details, Phase 2 results, Canadian trial sites
- [Compare Treatments](https://getretatrutide.ca/compare/): Retatrutide vs tirzepatide vs semaglutide — receptors, weight loss data, availability in Canada
- [How to Get in Canada](https://getretatrutide.ca/how-to-get/): Clinical trial enrollment, Health Canada Special Access Programme (SAP), warnings about unregulated products
- [Safety & Side Effects](https://getretatrutide.ca/safety/): Known side effects, serious risks, contraindications, gaps in current knowledge
- [News](https://getretatrutide.ca/news/): Latest clinical trial results, regulatory developments, Canadian analysis
- [Waitlist](https://getretatrutide.ca/waitlist/): Email signup for retatrutide availability updates in Canada

## French (fr-CA)

- [Accueil](https://getretatrutide.ca/fr/)
- [Qu'est-ce que le rétatrutide?](https://getretatrutide.ca/fr/what-is-retatrutide/)
- [Essais cliniques](https://getretatrutide.ca/fr/clinical-trials/)
- [Comparer](https://getretatrutide.ca/fr/compare/)
- [Accès au Canada](https://getretatrutide.ca/fr/how-to-get/)
- [Sécurité](https://getretatrutide.ca/fr/safety/)
- [Actualités](https://getretatrutide.ca/fr/news/)
- [Infolettre](https://getretatrutide.ca/fr/waitlist/)

## About this site

Independent educational resource. Not affiliated with Eli Lilly or any pharmaceutical company. Not a pharmacy, clinic, or medical practice. Editorial content only — not medical advice. No sponsored content or paid placement.

## Primary sources cited

- Jastreboff AM et al. NEJM 2023 (DOI: 10.1056/NEJMoa2301972)
- ClinicalTrials.gov: NCT05929066 (TRIUMPH-1), NCT05929079 (TRIUMPH-2), NCT06383390 (TRIUMPH-OUTCOMES), NCT05931367 (TRIUMPH-4), NCT06260722 (TRIUMPH-5)
- Eli Lilly investor press releases
- Health Canada Special Access Programme
- SURMOUNT-1 (NCT04184622), STEP-1 (NCT03548935)